Drug delivery and translational research

Designing fat-based nanoparticles to deliver cancer treatments directly to tumors

Updated

Abstract

Targeted anticancer therapies face challenges such as poor bioavailability and limited tumor penetration.

  • Current targeted therapies include monoclonal antibodies, antibody-drug conjugates, siRNA, small-molecule inhibitors, and PROTACs.
  • First-generation lipid-based nanoparticles (LBNPs) exploit the enhanced permeability and retention (EPR) effect but are insufficient alone due to tumor heterogeneity.
  • The design of LBNPs must consider the structural complexities and biological barriers of each therapeutic modality.
  • Optimizations for various nanocarriers involve customized lipid compositions, active targeting surface modifications, and the use of ionizable lipids to address endosomal entrapment.
  • Optimal administration routes are linked to these structural designs, with formulation methods varying from traditional emulsification to advanced techniques like microfluidics.
  • Clinical challenges for nanomedicines stem more from manufacturing and regulatory issues than from preclinical efficacy.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declarations. Competing interests: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free